Senti Bio gets additional $1.0 million tranche from CIRM grant for advancing clinical development of SENTI-202
Senti Biosciences, Inc., a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, reported the receipt of an additional $1.0 million from the California Institute of Regenerative …